Cancer Nanomedicine: Mechanisms, Obstacles and Strategies

Li, Huafei; Jin, Hai; Wan, Wei; Wu, Cong; Wei, Lixin

doi:10.2217/nnm-2018-0007

Cited by 45 publications

(22 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 2 ] However, due to the intrinsic limitations associated with those clinical modalities, the therapeutic efficacy very often exhibits decreased performance. [ 3 ] For example, patients receiving chemotherapy are subject to its accompanied side effects. This is because most of the anticancer drugs used in chemotherapy are poor water‐soluble, highly toxic, lack of targeting property, and developing multidrug resistance (MDR).…”

Section: Introductionmentioning

confidence: 99%

Organic/Inorganic Self‐Assembled Hybrid Nano‐Architectures for Cancer Therapy Applications

Yang

Lin

Chen

et al. 2021

Macromolecular Bioscience

View full text Add to dashboard Cite

Since the conceptualization of nanomedicine, numerous nanostructure‐mediated drug formulations have progressed into clinical trials for treating cancer. However, recent clinical trial results indicate such kind of drug formulations has a limited improvement on the antitumor efficacy. This is due to the biological barriers associated with those formulations, for example, circulation stability, extravasation efficiency in tumor, tumor penetration ability, and developed multi‐drug resistance. When employing for nanomedicine formulations, pristine organic‐based and inorganic‐based nanostructures have their own limitations. Accordingly, organic/inorganic (O/I) hybrids have been developed to integrate the merits of both, and to minimize their intrinsic drawbacks. In this context, the recent development in O/I hybrids resulting from a self‐assembly strategy will be introduced. Through such a strategy, organic and inorganic building blocks can be self‐assembled via either chemical covalent bonds or physical interactions. Based on the self‐assemble procedure, the hybridization of four organic building blocks including liposomes, micelles, dendrimers, and polymeric nanocapsules with five functional inorganic nanoparticles comprising gold nanostructures, magnetic nanoparticles, carbon‐based materials, quantum dots, and silica nanoparticles will be highlighted. The recent progress of these O/I hybrids in advanced modalities for combating cancer, such as, therapeutic agent delivery, photothermal therapy, photodynamic therapy, and immunotherapy will be systematically reviewed.

show abstract

Section: Introductionmentioning

confidence: 99%

Organic/Inorganic Self‐Assembled Hybrid Nano‐Architectures for Cancer Therapy Applications

Yang

Lin

Chen

et al. 2021

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…can accumulate in tumors by passive retention mechanism (so-called enhanced permeability and retention effect, EPR), due to the irregular epithelium, decreased interstitial fluid uptake, and weakened lymphatic drainage of tumor vasculature (Bertrand et al, 2014;H. Li, Jin, Wan, Wu, & Wei, 2018).…”

Section: Nanocarrier Descriptionmentioning

confidence: 99%

“…In case of drug delivery applications, nanoparticles have been shown to protect the drugs from degradation, improve their solubility, prolong blood half‐life and modulate pharmacokinetic properties, as well as to provide the targeted delivery and controlled drug release (Bertrand, Wu, Xu, Kamaly, & Farokhzad, ). What is more, it has been found that nanoparticles can accumulate in tumors by passive retention mechanism (so‐called enhanced permeability and retention effect, EPR), due to the irregular epithelium, decreased interstitial fluid uptake, and weakened lymphatic drainage of tumor vasculature (Bertrand et al, ; H. Li, Jin, Wan, Wu, & Wei, ). The possibility of conjugation of nanoparticles with targeting moieties such as peptides, antibodies, carbohydrates, or folic acid can further enhance specific transport of the drugs to their sites of action (Friedman, Claypool, & Liu, ).…”

Section: Nanotechnology For Enhanced Efficiency Of Pdtmentioning

confidence: 99%

Nanocarriers in photodynamic therapy—in vitro and in vivo studies

Sztandera

Gorzkiewicz

Klajnert‐Maculewicz

2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a minimally invasive technique which has proven to be successful in the treatment of several types of tumors. This relatively simple method exploits three inseparable elements: phototoxic compound (photosensitizer [PS]), light source, and oxygen. Upon irradiation by light with specified wavelength, PS generates reactive oxygen species, which starts the cascade of reactions leading to cell death. The positive therapeutic outcome of PDT may be limited due to several aspects, including low water solubility of PSs, hampering their effective administration and blood circulation, as well as low tumor specificity, inefficient cellular uptake and activation energies requiring prolonged illumination times. One of the promising approaches to overcome these obstacles involves the use of carrier systems modulating pharmacokinetics and pharmacodynamics of the PSs. In the present review, we summarized current in vitro and in vivo studies regarding the use of nanoparticles as potential delivery devices for PSs to enhance their cellular uptake and cytotoxic properties, and thus—the therapeutic outcome of PDT. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

“…These theranostic SPION-DOX PNP thus reflect the real-time characteristics of the tumor in each patient and could allow for earlier disease detection, more accurate prognostic information and an enhanced ability to monitor the efficacy of treatment [15]. Besides, the evaluation of the NP accumulation in healthy tissues would allow us to assess the risk of patients developing off-target side effects or to screen patients who are likely to respond positively to the treatment [16].…”

Section: Introductionmentioning

confidence: 99%

SPION and doxorubicin-loaded polymeric nanocarriers for glioblastoma theranostics

Luque-Michel

Lemaire

Blanco-Prieto

2021

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Glioma is a type of cancer with a very poor prognosis with a survival of around 15 months in the case of glioblastoma multiforme (GBM). In order to advance in personalized medicine, we developed polymeric nanoparticles (PNP) loaded with both SPION (Superparamagnetic Iron Oxide Nanoparticles) and doxorubicin (DOX). The former being used for its potential to accumulate the PNP in the tumor under a strong magnetic field and the later for its therapeutic potential. The emulsion solvent and evaporation method was selected to develop monodisperse PNP with high loading efficiency in both SPION and DOX.Once injected in mice, a significant accumulation of the PNP was observed within the tumoral tissue under static magnetic field as observed by MRI leading to a reduction of tumor growth rate.

show abstract

Cancer Nanomedicine: Mechanisms, Obstacles and Strategies

Cited by 45 publications

References 156 publications

Organic/Inorganic Self‐Assembled Hybrid Nano‐Architectures for Cancer Therapy Applications

Organic/Inorganic Self‐Assembled Hybrid Nano‐Architectures for Cancer Therapy Applications

Nanocarriers in photodynamic therapy—in vitro and in vivo studies

SPION and doxorubicin-loaded polymeric nanocarriers for glioblastoma theranostics

Contact Info

Product

Resources

About